1-Methyl-5-(N-methylcarbamoyl)-imidazol | 53525-61-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-Methyl-5-(N-methylcarbamoyl)-imidazol
• 英文别名: 3-methyl-3H-imidazole-4-carboxylic acid methylamide；N,1-Dimethyl-1H-imidazole-5-carboxamide；N,3-dimethylimidazole-4-carboxamide
• CAS: 53525-61-4
• 化学式: C₆H₉N₃O
• 分子量: 139.157
• InChiKey: WOIFYVMQXDZNHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
  申请人：Pinto J. P. Donald

  公开号：US20080090807A1

  公开（公告）日：2008-04-17

  The present application describes lactam-containing compounds and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

  本申请描述了一类含有内酰胺的化合物及其衍生物，其化学式为I：或其药学上可接受的盐形式，其中，如果存在环P，则为5-7成员的碳环或杂环，环M为5-7成员的碳环或杂环。本发明的化合物可用作胰蛋白酶样丝氨酸蛋白酶抑制剂，特别是因子Xa的抑制剂。
• Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds
  申请人：Guiles Joseph

  公开号：US20120015941A1

  公开（公告）日：2012-01-19

  The present invention provides novel amide and sulfonamide substituted heterocyclic urea compounds having useful antibacterial activity. Use of these compounds as pharmaceutical compositions and method of their production are also provided.

  本发明提供了一种具有有用的抗菌活性的新型酰胺和磺酰胺取代的杂环脲化合物。还提供了这些化合物作为药物组成物的使用和它们的制备方法。
• US7531535B2
  申请人：——

  公开号：US7531535B2

  公开（公告）日：2009-05-12
• US8148380B2
  申请人：——

  公开号：US8148380B2

  公开（公告）日：2012-04-03
• [EN] INHIBITORS OF TRANSGLUTAMINASES<br/>[FR] INHIBITEURS DE TRANSGLUTAMINASES
  申请人：ZEDIRA GMBH

  公开号：WO2018122419A1

  公开（公告）日：2018-07-05

  The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use for the prophylaxis and treatment of diseases associated with transglutaminases.